Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000760647 | SCV000890539 | pathogenic | not provided | 2018-07-25 | criteria provided, single submitter | clinical testing | The E2667X variant in the USH2A gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The E2667X variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016). We interpret E2667X as a pathogenic variant. |
Labcorp Genetics |
RCV000760647 | SCV001407006 | pathogenic | not provided | 2023-10-18 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Glu2667*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with Usher syndrome (Invitae). ClinVar contains an entry for this variant (Variation ID: 620283). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV003453570 | SCV004183185 | pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV004569425 | SCV005055755 | likely pathogenic | Retinitis pigmentosa 39 | 2023-12-23 | criteria provided, single submitter | clinical testing |